Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy

European Journal of Cancer

Volumn 40, Issue 4, 2004, Pages 594-605

  Walker, J ^a   Martin, C ^a   Callaghan, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Multidrug resistance; P glycoprotein; Solid tumour model; XR9576

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; TARIQUIDAR; VINBLASTINE;

ARTICLE; CANCER MODEL; CANCER RESISTANCE; CARCINOSARCOMA; CELL ASSAY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MONOLAYER CULTURE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION;

EID: 1242338943     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.09.036     Document Type: Article

References (64)

1. Tannock I.F., Goldenberg G.J. Drug resistance and experimental chemotherapy. Tannock I.F., Hill R.P. The Basic Science of Oncology. 3rd edn:1998;370-391 McGraw-Hill, London.
2. Baguley B. A brief history of cancer chemotherapy. Baguley B., Kerr D.J. Anticancer Drug Development. 2002;1-9 Academic Press, London.
3. Boyer M.J., Tannock I.F. Cellular and molecular basis of chemotherapy. Tannock I.F., Hill R.P. The Basic Science of Oncology. 3rd edn:1998;370-391 McGraw-Hill, London.
4. Skeel R.T. Biologic and pharmacologic basis of cancer chemotherapy. Skeel R.T. Handbook of Cancer Chemotherapy. 1999;3-20 Lippincott Williams and Wilkins, Philadelphia, PA.
5. Kasimir-Bauer S., Beelen D., Flasshove M., Noppeney R., Seeber S., Scheulen M.E. Impact of the expression of P glycoprotein, the multidrug resistance- related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol. 30:2002;1302-1308.
6. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer. role of ATP-dependent transporters Nat Rev Cancer. 2:2002;48-58.
7. Robert J. Resistance to cytotoxic agents. Curr Opin Pharmacol. 1:2001;353-357.
8. Inoue S., Salah-Eldin A.E., Omoteyama K. Apoptosis and anticancer drug resistance. Hum Cell. 14:2001;211-221.
9. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood. 98:2001;2603-2614.
10. Chauncey T.R. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol. 13:2001;21-26.
11. Mow B.M., Blajeski A.L., Chandra J., Kaufmann S.H. Apoptosis and the response to anticancer therapy. Curr Opin Oncol. 13:2000;453-462.
12. Leonard G.D., Polgar O., Bates S.E. ABC transporters and inhibitors. new targets, new agents Curr Opin Investig Drugs. 3:2002;1652-1659.
13. Ro J., Sahin A., Ro J.Y., Fritsche H., Hortobagyi G., Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol. 21:1990;787-791.
14. Sonneveld P. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer. 32A:1996;1062-1069.
15. van den Heuvel-Eibrink M.M., Sonneveld P., Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther. 38:2000;94-110.
16. Schneider J., Bak M., Efferth T., Kaufmann M., Mattern J., Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer. 60:1989;815-818.
17. Chan H.S., Haddad G., Thorner P.S., DeBoer G., Lin Y.P., Ondrusek N.et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 325:1991;1608-1614.
18. Goldstein L.J. MDR1 gene expression in solid tumours. Eur J Cancer. 32A:1996;1039-1050.
19. Chan H.S., Grogan T.M., Haddad G., DeBoer G., Ling V. P-glycoprotein expression. critical determinant in the response to osteosarcoma chemotherapy J Natl Cancer Inst. 89:1997;1706-1715.
20. Lum B., Gosland M.P., Kaubisch S., Sikic B.I. Molecular targets in oncology. implications of the multidrug resistance gene Pharmacotherapy. 13:1993;88-109.
21. Fields A., Hochster H., Runowicz C., Speyer J., Goldberg G., Cohen C.et al. PSC833. initial clinical results in refractory ovarian cancer patients Curr Opin Oncol. 10(Suppl. 1):1998;S21.
22. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M.et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:1996;4171-4179.
23. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer. 72:1993;3553-3563.
24. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res. 51:1991;4226-4233.
25. Dale I.L., Tuffley W., Callaghan R.et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 78:1998;885-982.
26. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Research. 53:1993;4595-4602.
27. Mistry P., Bootle D., Liddle C., Loi R., Templeton D. Reversal of P-glycoprotein mediated multidrug resistance in vivo by XR9576. Ann. Oncol. 9:1998;. (Abstract 568).
28. Stewart A., Steiner J., Mellows G., Laguda B., Norris D., Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin. Cancer Res. 6:2000;4186-4191.
29. Desoize B., Gimonet D. Jardiller, J-C. Cell culture as spheroids: an approach to multicellular resistance. Anticancer Research. 18:1998;4147-4158.
30. Durand R.E., Olive P.L. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol. 64:2001;211-233.
31. Kunz-Schughart L.A., Kreutz M., Knuechel R. Multicellular spheroids. a three-dimensional in vitro culture system to study tumour biology Int J Exp Pathol. 79:1998;1-23.
32. Kaye S.B. Clinical drug resistance. the role of factors other than P-glycoprotein Am. J. Medicine. 99:1995;40S-44S.
33. Kaye S.B. Multidrug resistance in breast cancer - is the jury in yet? J Natl Cancer Inst. 89:1997;902-903.
34. Kaye S.B. Multidrug resistance. clinical relevance in solid tumours and strategies for circumvention Curr. Opin. Oncol. 10(Suppl. 1):1998;S15-S19.
35. Batist G., Tulpule A., Sinha B.K., Katki A.G., Myers C.E., Cowan K.H. Overexpression of a novel anionic glutathione transferase in multidrug- resistant human breast cancer cells. J. Biol. Chem. 261:1986;15544-15549.
36. Scudiero D.A., Monks A., Sausville E.A. Cell line designation change. multidrug-resistant cell line in the NCI anticancer screen J Natl Cancer Inst. 90:1998;862.
37. Kunz-Schughart L.A., Meuller-Klieser W. Three-dimensional culture. Masters J.R.W. Animal Cell Culture. 3rd edn:2000;123-148 Oxford University Press, Oxford.
38. Kiernan J.A. Histological and Histochemical Methods. 2000;Butterworth Heinemann, Oxford.
39. Magaud J.P., Sargent I., Clarke P.J., Ffrench M., Rimokh R., Mason D.Y. Double immunocytochemical labeling of cell and tissue samples with monoclonal anti-bromodeoxyuridine. J. Histochem. Cytochem. 37:1989;1517-1527.
40. De Lean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves. applications to bioassay, radioligand assay, and physiological dose-response curves Am. J. Physiol. 235:1978;E97-E102.
41. Wartenberg M., Frey C., Diedershagen H., Ritgen J., Hescheler J., Sauer H. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer. 75:1998;855-863.
42. Tunggal J.K., Cowan D.S., Shaikh H., Tannock I.F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 5:1999;1583-1586.
43. Durand R.E. Slow penetration of anthracyclines into spheroids and tumors. a therapeutic advantage? Cancer Chemother Pharmacol. 26:1990;198-204.
44. Hall MD, Martin C, Ferguson DJP, Phillips RM, Hambley TW, Callaghan R. Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochem Pharmacol [in press] doi:10.1016/j.bcp.2003.07.016.
45. Desoize B., Jardillier J. Multicellular resistance. a paradigm for clinical resistance? Crit Rev Oncol Hematol. 36:2000;193-207.
46. Mattern J., Kallinowski F., Herfarth C., Volm M. Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer. 67:1996;20-23.
47. Shain K.H., Dalton W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 1:2001;69-78.
48. Trock B.J., Leonessa F., Clarke R. Multidrug resistance in breast cancer. a meta-analysis of MDR1/gp170 expression and its possible functional significance J Natl Cancer Inst. 89:1997;917-931.
49. Holzmayer T.A., Hilsenbeck S., Von Hoff D.D., Roninson I.B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 84:1992;1486-1491.
50. Eichholtz-Wirth H. Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. Br J Cancer. 41:1980;886-891.
51. Matsushima Y., Kanzawa F., Hoshi A., Shimizu E., Nomori H., Sasaki Y.et al. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol. 14:1985;104-107.
52. Rupniak H.T., Whelan R.D., Hill B.T. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int J Cancer. 32:1983;7-12.
53. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S., Egorin M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8:2002;878-884.
54. Martin C., Walker J., Rothnie A., Callaghan R. The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models. Br. J. Cancer. 89:2003;1581-1589.
55. Nederman T., Carlsson J., Kuoppa K. Penetration of substances into tumour tissue. Model studies using saccharides, thymidine and thymidine-5′-triphosphate in cellular spheroids. Cancer Chemother Pharmacol. 22:1988;21-25.
56. Kerr D.J., Wheldon T.E., Hydns S., Kaye S.B. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica. 18:1988;641-648.
57. Gardner S.N. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and-nonspecific drugs. Cancer Res. 60:2000;1417-1425.
58. Moore M.J., Erlichman C. Pharmacology of anticancer drugs. Tannock I.F., Hill R.P. The Basic Science of Oncology. 3rd edn:1998;370-391 McGraw-Hill, London.
59. Martin C., Berridge G., Mistry P., Higgins C., Charlton P., Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128:1999;403-411.
60. Cowan K.H., Batist G., Tulpule A., Sinha B.K., Myers C.E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl. Acad. Sci. U.S.A. 83:1986;9328-9332.
61. Carlsson J., Nederman T. A method to measure the radio and chemosensitivity of human spheroids. Adv Exp Med Biol. 159:1983;399-417.
62. Ivy S.P., Tulpule A., Fairchild C.R., Averbuch S.D., Myers C.E., Nebert D.W.et al. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF- 7 human breast cancer cell line. J. Biol. Chem. 263:1988;19119-19125.
63. Phillips R.M., Loadman P.M., Cronin B.P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer. 77:1998;2112-2119.
64. Lai G.M., Chen Y.N., Mickley L.A., Fojo A.T., Bates S.E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 49:1991;696-703.